This has been a bad year for Biogen (NASDAQ: BIIB)so far -- the biotech's stock has dropped more than 10% since it began. But 2018 has been horrible for Acadia Pharmaceuticals (NASDAQ: ACAD), which has seen its share price plunge nearly 40%.
Better Buy: Acadia Pharmaceuticals vs. Biogen
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться